



# Clinical Trials Regulation

## Why, when, what and how ?

*Sylvain Giraud, Head of Unit*

*DG SANTE B4*

*Medical products: quality, safety, innovation*

# Content

- Why – purpose of the CTR
- When – timeline for the CTR
- What – new concepts in the CTR
- How - Guidance documents, expert groups and Committees

# Under the Clinical Trial Directive




- The **number of applications** for authorisation to clinical trials in the EU **decreased by 25%** between 2007 and 2011
- The **costs** of conducting clinical trials **increased**
- And the **average waiting time** for clinical trials **increased by 90%** (152 days) (Tenti et al, 2018)

In **2012**, the European Commission proposed a new **Regulation**





# Timeline for the CTR



- **EMA MB endorsement** of full functionality is a condition for the publication of the notice in the official journal and was confirmed on 21/04/2021. 6 months later, the CTR starts to apply
- The *expected* date of application is **January 31, 2022** - the actual date depends on the publication of the Notice in the OJ

# New concepts in the CTR



- **Adapted definitions** on clinical trial, introducing low-intervention clinical trials
- Streamlined **submission and review process via EU Portal and Database** (EUPD) including a **tacit approval** system
- **Single decision** per Member State (= / NCA + Ethics Committee)
- **Coordinated assessment** with one **Reporting Member State**, proposed by the sponsor and **involvement of all Member States Concerned**

# New concepts in the CTR (2)



- Strengthened patients' protection and **informed consent**, specific modalities on **cluster trials**
- Strengthened **independence** of persons **validating** and/or **assessing** the application
- **Coordinated safety assessment** through work-sharing and **streamlined safety reporting**
- **More transparency** on the conduct and results of the clinical trial
- The possibility for the **Commission to conduct controls** in Member States and third countries on the CT systems

7



# Guidance documents, training

- DG SANTE (CTEG) guidance documents: EudraLex-Volume 10
- Collaboration with EMA and CTFG
- Separately for the Directive 2001/20/EC and the Regulation (EU) No 536/2014

[Home](#) [All topics](#) [Medicinal products](#)

## EudraLex - Volume 10 - Clinical trials guidelines

Volume 10 of the publication "The rules governing medicinal products in the European Union" contains guidance documents applying to clinical trials.

A number of documents in Volume 10 are being revised and updated to bring them in line with the changes required by the Clinical Trials Regulation (EU) No 536/2014. Additionally, new documents were prepared to cover new aspects introduced by the same Regulation.

In order to make a distinction between documents applicable to clinical trials authorised under Directive 2001/20/EC (i.e. the current applicable documents) and documents relevant to clinical trials authorised under Regulation (EU) No 536/2014, these documents will be listed in two separate pages on the Eudralex Volume 10 website.

Until the Clinical Trials Regulation becomes applicable sponsors should follow the documents relevant to the Clinical Trials Directive.

During the transitional period, which will last for a period of 3 years starting from when the Regulation becomes applicable, both sets of documents will apply accordingly and should be referred to respectively according to the legislation under which the Clinical trial is conducted.

At the end of the transitional period all clinical trials shall be conducted under the Regulation and should follow only the set of documents applicable to the Regulation.

Although it is not mandatory, stakeholders are encouraged to take already into consideration a number of aspects that are outlined in the new or updated documents published in the page dedicated to the Clinical Trial Regulation and apply them to those clinical trials authorised under the Directive, to the extent possible and in compatibility with the legal framework of the Directive.

[Browse the theme](#)

- Set of documents applicable to clinical trials authorised under Directive 2001/20/EC
- **Set of documents applicable to clinical trials that will be authorised under Regulation EU No 536/2014, once it becomes applicable**

⇒ **Set of documents applicable to clinical trials that will be authorised under Regulation EU No 536/2014, once it becomes applicable**

Chapter I - Application and application documents

- Part II application document templates
  - Investigator Curriculum Vitae template: [pdf](#) [word](#)
  - Declaration of interest template: [pdf](#) [word](#)

Chapter II - Safety reporting

- ICH guideline E2F - Note for guidance on development safety update reports [\(September 2010\)](#)

For more guidance on safety reporting please refer to the Q&A document on the Clinical Trials Regulation in Chapter V

Chapter III - Quality

- Template for the qualified person's declaration equivalence to EU GMP for Investigational Medicinal Products manufactured in third countries : [PDF version](#) - [Word version](#) (may 2013)

[https://ec.europa.eu/health/documents/eudralex/vol-10\\_en](https://ec.europa.eu/health/documents/eudralex/vol-10_en)





# Clinical Trials Expert Group (CTEG)

- **Type:** non-public meeting, informal group
- **Organizer and chair:** DG SANTE, European Commission
- **Attendees:** 1 representative from **NCA and EC** per MS, EMA observer.
- **Meeting:** at the moment, 4 times/year, with thematic *ad hoc* meetings as necessary
- **Purpose CT EG:**
  - To provide the COM with advice and expertise on clinical trials in relation to the preparation and implementation of legislation and policy initiatives.
  - Draw up and adopt guidelines and documents related to the transition from the CTD to the CTR and to the implementation of the Regulation

# Clinical Trials Coordination and Advisory Group (CTAG)

- **Type:** non-public meeting, formal group established by the CTR art. 85
- **Organizer and chair:** DG SANTE, European Commission
- **Attendees:** 1 representative per MS (national contact point), EMA.
- **Meetings:** regular and *ad hoc* when necessary
- **Purpose CTAG**
  - support the exchange of information on the experience acquired with regard to the implementation of this Regulation
  - assist the Commission in providing the support on coordinated safety assessment
  - prepare recommendations on criteria regarding the selection of a RMS

# National contact points

- Designated by the Member States (one/MS)
- List is public:  
[https://ec.europa.eu/health/sites/health/files/files/clinicaltrials/contact-points\\_clinical-trials\\_reg-536-2014.pdf](https://ec.europa.eu/health/sites/health/files/files/clinicaltrials/contact-points_clinical-trials_reg-536-2014.pdf)
- Function:
  - Facilitate procedures in initial trial applications and applications for substantial modifications
  - Members of the CTAG

# Additional collaborations

- Training: joint COM/EMA/CTFG-HMA trainings to sponsors and authorities
- CTIS development: coordinated jointly by EMA, COM with MS involvement
- IA for coordinated safety assessment: EMA/CTFG/COM drafting team (joint CTEG/CTFG review)
- Joint guidelines e.g.:
  - Joint COVID-19/CT Guidance
  - General QnA for CTR (safety chapter by CTFG)
  - Guideline to interface IVDR/CTR (in progress, driven by CTFG)

THANK YOU FOR YOUR ATTENTION



DG SANTE B4 Clinical Trial Team

SANTE-PHARMACEUTICALS-B4@ec.europa.eu

